| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5320 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2768 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1663 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1333 | 2021 |
| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 923 | 2022 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 737 | 2021 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 588 | 2021 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 334 | 2021 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 278 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial J Frater, KJ Ewer, A Ogbe, M Pace, S Adele, E Adland, J Alagaratnam, ... The lancet HIV 8 (8), e474-e485, 2021 | 216 | 2021 |
| Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial M Madhavan, AJ Ritchie, J Aboagye, D Jenkin, S Provstgaad-Morys, ... EBioMedicine 85, 2022 | 74 | 2022 |
| AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific TH1 response with a diverse TCR repertoire PA Swanson, M Padilla, W Hoyland, K McGlinchey, PA Fields, S Bibi, ... Science translational medicine 13 (620), eabj7211, 2021 | 74 | 2021 |
| Oxford COVID Vaccine Trial Group Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised … PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... Lancet 396 (10249), 467-478, 2020 | 68 | 2020 |
| COVID-19 Genomics UK consortium; AMPHEUS Project KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... Oxford COVID-19 Vaccine Trial Group. Efficacy of ChAdOx1 nCoV-19 (AZD1222 …, 2021 | 52 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil SAC Clemens, PM Folegatti, KRW Emary, LY Weckx, J Ratcliff, S Bibi, ... Nature Communications 12 (1), 5861, 2021 | 46 | 2021 |
| A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial PM Folegatti, K Harrison, L Preciado-Llanes, FR Lopez, M Bittaye, YC Kim, ... Nature communications 12 (1), 4636, 2021 | 44 | 2021 |
| Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV A Ogbe, M Pace, M Bittaye, T Tipoe, S Adele, J Alagaratnam, PK Aley, ... JCI insight 7 (7), 2022 | 30 | 2022 |
| T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire PA Swanson, M Padilla, W Hoyland, K McGlinchey, PA Fields, S Bibi, ... MedRxiv, 2021.06. 17.21259027, 2021 | 24 | 2021 |
| Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment PM Folegatti, D Jenkin, S Morris, S Gilbert, D Kim, JS Robertson, ... Vaccine 40 (35), 5248-5262, 2022 | 14 | 2022 |
| Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial D Jenkin, AJ Ritchie, J Aboagye, S Fedosyuk, L Thorley, ... The Lancet Microbe 3 (9), e663-e671, 2022 | 10 | 2022 |
Sarah C GilbertProfessor of Vaccinology, Pandemic Sciences Institute, Oxford Universityایمیل تأیید شده در ndm.ox.ac.uk
